Immunome Inc. Files 8-K on Operations and Financials
Ticker: IMNM · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, reporting
TL;DR
Immunome filed an 8-K for ops/financials - check for details.
AI Summary
Immunome, Inc. filed an 8-K on August 12, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details in the provided text, but indicates a formal reporting event.
Why It Matters
This filing serves as a formal notification to investors and the public regarding Immunome's operational and financial status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing reporting operational and financial information, not indicating any immediate adverse events.
Key Players & Entities
- Immunome, Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Address of principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The provided text of the 8-K filing does not contain specific financial figures or detailed results of operations. It only indicates that the filing pertains to these items.
What is the primary purpose of this 8-K filing for Immunome, Inc.?
The primary purpose of this 8-K filing is to report on Immunome, Inc.'s results of operations and financial condition, and to file financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 12, 2024.
Where are Immunome, Inc.'s principal executive offices located?
Immunome, Inc.'s principal executive offices are located at 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011.
What is the Commission File Number for Immunome, Inc.?
The Commission File Number for Immunome, Inc. is 001-39580.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-12 16:05:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
Filing Documents
- tm2421310d1_8k.htm (8-K) — 27KB
- tm2421310d1_ex99-1.htm (EX-99.1) — 74KB
- 0001104659-24-088340.txt ( ) — 279KB
- immu-20240812.xsd (EX-101.SCH) — 3KB
- immu-20240812_lab.xml (EX-101.LAB) — 33KB
- immu-20240812_pre.xml (EX-101.PRE) — 22KB
- tm2421310d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 12, 2024, Immunome, Inc. (the "Company") announced its financial results for the second quarter ended June 30, 2024 and provided a business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated August 12, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 12, 2024 Immunome, Inc. By: /s/ Max Rosett Name: Max Rosett Title: Chief Financial Officer